Cross Currents: ADCs After EGFR TKI Progression in EGFR-Mutated NSCLC

Oncologists from the US and China discussed the efficacy of antibody-drug conjugates (ADCs) for treating EGFR-mutated non–small cell lung cancer following TKI therapy. Clinical trial results presented at the 2026 ESMO Congress showed significant improvements in survival rates for patients using these new therapies.
Why it matters
These findings represent a major advancement in targeted cancer therapy, offering new treatment options for patients who have exhausted standard TKI options.
"Because the toxicity exists, I see the ADC as a delivery system of the chemotherapy. So it’s not chemo-free."
In a 3-part video series recorded at the 2026 ESMO Congress, Li Zhang, MD, a professor in the Department of Medical Oncology and deputy director of the Lung Cancer Research Center at Sun Yat-sen University Cancer Center, discussed the role of antibody-drug conjugates (ADCs) for patients with EGFR-mutated non–small cell lung cancer (NSCLC) whose disease has progressed on EGFR tyrosine kinase inhibitors (TKIs), focusing on sacituzumab tirumotecan (sac-TMT) and izalontamab brengitecan (iza-bren).
The discussion is part of Cross Currents: Where East Meets West in Cancer Care, a video series produced through a collaboration between OncLive and China-based digital health platform DXY. In Cross Currents, oncologists from the United States and China compare clinical practice in their regions and discuss key data from major meetings.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in